课题基金 / 基金详情

BR96-DOXORUBICIN CONJUGATE IN METASTATIC BREAST CANCER

BR96-DOXORUBICIN CONJUGATE IN METASTATIC BREAST CANCER
BR96-阿霉素缀合物治疗转移性乳腺癌
批准号：
6244047
负责人：
MANSOOR N SALEH
金额：
$2.46万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-10 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244047
关键词：
breast neoplasms clinical research combination cancer therapy doxorubicin drug screening /evaluation female human subject human therapy evaluation immunoconjugates metastasis monoclonal antibody neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy pharmacokinetics women's health

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a multi-institutional, open label, two-arm, randomized phase II trial of BMS-182248-01 administered every 21 days vs. doxorubicin given every 21 days. The objectives of this study are to: 1) assess the objective response rate of each treatment arm; 2) evaluate the duration of response for each treatment regimen; 3) evaluate the safety profile of BMS-182248-01 and doxorubicin; 4) assess the objective resonse rates after crossover.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金